KUMC

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2023

Retrieved on: 
Thursday, May 11, 2023
Exercise, HRSA, Heart, Omicron, CPT, Dana–Farber Cancer Institute, Harvard University, Internet, Genomics, COVID-19, Diagnosis, Medicine, Research, Absorption, Doctor of Philosophy, Sale, Whole genome sequencing, Public expenditure, Eurofins Scientific, CLIA, Baylor University, Nebula Genomics, EBITDA, Acquisition, Collection, KUMC, Corporation, Hospital Insurance and Diagnostic Services Act, WGS, Growth, Prophase, FDM, Galway-Mayo Institute of Technology, Three Months, Food, Creative industries, Cryptocurrency, Pharmaceutical industry, Dietary supplement, Antibiotics, Security (finance), MD

Garden City, NY, May 11, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2023.

Key Points: 
  • Financial highlights for the three months ended March 31, 2023, include the following:
    Net revenue of $19.3 million for the three months ended March 31, 2023, as compared to $47.5 million for the three months ended March 31, 2022.
  • Adjusted EBITDA of $3.1 million for the three months ended March 31, 2023, as compared to adjusted EBITDA of $14.6 million for the three months ended March 31, 2022.
  • For the three months ended March 31, 2023, net revenue was $19.3 million as compared to $47.5 million for the three months ended March 31, 2022.
  • Diagnostic services costs for the three months ended March 31, 2023 were $1.2 million compared to $4.7 million for the three months ended March 31, 2022.

XCPCNL Business Services Announces Official Closing of Centiment Capital IO

Retrieved on: 
Tuesday, December 20, 2022
Crypto, Manta, Algorithm, Data analysis, MIT, OTC Markets Group, EIQ, KUMC, Research, Movement, Acquisition, Ingestion, AI, Keyword Services Platform, University of Kansas School of Medicine, Integration, Machine learning, University, Intelligence, University of Kansas School of Business, Content, EQS, Massachusetts Institute of Technology, Music, Cryptocurrency

Charlotte, North Carolina, Dec. 20, 2022 (GLOBE NEWSWIRE) -- XCPCNL Business Services Corporation (OTC Pink: XCPL), a venture development business that leverages knowledge, skill, and experience in the consumer products industry, is excited to announce the successful closing of Centiment Capital IO.

Key Points: 
  • Charlotte, North Carolina, Dec. 20, 2022 (GLOBE NEWSWIRE) -- XCPCNL Business Services Corporation (OTC Pink: XCPL), a venture development business that leverages knowledge, skill, and experience in the consumer products industry, is excited to announce the successful closing of Centiment Capital IO.
  • In other words, the EiQ knows where the crowd is headed before the crowd becomes cognizant.
  • The algorithms have high EQs, read markets and apply neural-based sentiment models
    Mantis Prime will be the proprietary trading business arm of XCPCNL now that the acquisition of Centiment Capital is complete.
  • XCPCNL Business Services Corporation (OTC Pink: XCPL) encourages shareholders to visit their corporate Twitter account at https://twitter.com/RealXCPCNL .

Aetna Teams with Community Partners to Help Kansans Lead Healthier Lives

Retrieved on: 
Wednesday, June 1, 2022
Community engagement, Caregiver, Adult, Doctor of Philosophy, Disability in Canada, Nursing, DSW, KCDD, Housing, Health, Name, Knowledge, Pharmacist, Solution, Quality of life, Population, Heart, Institute, Kansas Association of Broadcasters, Conditional sentence, Mental health, Organization, University, Physician, CVS Health, University of Kansas Medical Center, ECHO, Curriculum, Research, School, Disability, Medicare, Investment, Practitioner, Center, KUMC, Residential care, Medicine, Pharmaceutical industry, Health insurance, Medicaid

TOPEKA, Kan., June 1, 2022 /PRNewswire/ -- Aetna Better Health of Kansas, a CVS Health company, announced that it provided donations totaling $125,000 to five community health partners throughout the state. The donations will support health care providers and help the community meet health and social care needs, such as those related to mental health, developmental disabilities and housing.

Key Points: 
  • The donations will support health care providers and help the community meet health and social care needs, such as those related to mental health, developmental disabilities and housing.
  • "Community resources are essential for helping individuals and families achieve better health," said Lisa Baird, Chief Operating Officer, Aetna Better Health of Kansas.
  • By working together, we can make a difference in the lives of those in underserved communities in Kansas."
  • Currently, Aetna Medicaid owns and/or administers Medicaid managed health care plans under the names of Aetna Better Health and other affiliate names.

Impulse Dynamics Launches Optimizer Smart Mini CCM Delivery System

Retrieved on: 
Friday, April 29, 2022
Rhea, Cyclic permutation, Heart failure, LinkedIn, CE marking, Patient, Twitter, FDA, GLOBE, NYHA, Technology, Heart rate, Quality of life, Children's Mercy Hospital, Longevity, CCM, HF, Heart, CRT, University, Population, University of Kansas Medical Center, KUMC, Electrophysiology, Medical device, Pharmaceutical industry, Facebook

MARLTON, N.J., April 29, 2022 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce today both FDA and CE Mark approval and the official commercial launch of the Optimizer Smart Mini CCM therapy delivery system.

Key Points: 
  • MARLTON, N.J., April 29, 2022 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce today both FDA and CE Mark approval and the official commercial launch of the Optimizer Smart Mini CCM therapy delivery system.
  • Weve had a lot of experience with CCM using the Optimizer Smart device, but the next generation Optimizer Smart Mini CCM is simpler to implant and more comfortable for patients.
  • The Optimizer Smart Mini is a major advance for CCM therapy.
  • The Optimizer Smart Mini delivers CCM therapy the companys proprietary technology to the heart.

XCPCNL Business Services Announces Launch of First Product from Centiment Capital Holdings Partnership

Retrieved on: 
Tuesday, April 5, 2022
Bitcoin, Company, University, Partnership, API, Marketing, Forward-looking statement, Software as a service, MIT, Research, InMe, Intelligence, Keyword Services Platform, Manta, University of Kansas School of Law, Software, University of Kansas School of Medicine, EIQ, Industry, Technology, Massachusetts Institute of Technology, Knowledge, Securities Exchange Act of 1934, Twitter, Person, Securities Act of 1933, Acquisition, Machine learning, KUMC, EQS, GLOBE, Micah, News, Social media, AI, OTC Markets Group, Movement, Algorithm, Cryptocurrency, Financial services, Management, Security (finance), Crypto

Mantis Prime will be the proprietary trading business arm of XCPCNL once the acquisition of Centiment Capital is complete.

Key Points: 
  • Mantis Prime will be the proprietary trading business arm of XCPCNL once the acquisition of Centiment Capital is complete.
  • XCPCNL Business Services Corporation (OTC Pink: XCPL) encourages shareholders to visit their corporate Twitter account at https://twitter.com/RealXCPCNL .
  • Charlotte, NC-based XCPCNL Business Services is a venture development business that leverages its knowledge, skills, and experience in the consumer products industry.
  • Our primary mission is to provide marketing, technology, and other business services to fast-growing consumer product companies and big-box retailers.

CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease

Retrieved on: 
Tuesday, November 9, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Neurodegeneration, Government budget balance, Cognition, LC, Hippocampus, Safety, Maintenance, Neuron, Parkinson's disease, Circulator, Therapy, MD, Even and odd functions, Perfusion, KUMC, Palpitations, Doctor of Philosophy, Â, Locus coeruleus, Amygdala, Arousal, Patient, Tremor, Research, RBD, Memory, Central nervous system, Thalamus, Heart rate, Clenbuterol, Brain, Pharmaceutical industry, Medical imaging

Eight patients with mild cognitive impairment or Parkinsons disease were administered a single 80 g (microgram) dose of CST-103.

Key Points: 
  • Eight patients with mild cognitive impairment or Parkinsons disease were administered a single 80 g (microgram) dose of CST-103.
  • Patients who received the initial dose of CST-103 showed significant increases in cerebral blood flow in multiple areas of the brain, including the hippocampus.
  • Increases in cerebral blood flow were consistent one week later in patients who received a second dose of CST-103 as monotherapy.
  • The trials include patients with mild cognitive impairment, Parkinsons disease with rapid eye movement sleep disorder (RBD), Lewy body dementia, and mild cognitive impairment or mild dementia due to either Parkinson's or Alzheimers disease.

Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

Retrieved on: 
Wednesday, September 8, 2021

"Radiographic responses have been observed across multiple KRAS mutation variants, which speaks to a key advantage of onvansertib over competing agents targeting individual mutations.

Key Points: 
  • "Radiographic responses have been observed across multiple KRAS mutation variants, which speaks to a key advantage of onvansertib over competing agents targeting individual mutations.
  • The newly announced data are being discussed today at 4:00 PM ET as part of a key opinion leader (KOL) webinar being hosted by Cardiff Oncology.
  • A replay of the webinar will be available by visiting the " Events " section of the Cardiff Oncology website shortly after its conclusion.
  • Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need.

nCoup Communications: nCartes EHR to EDC platform contributes at 2021 AACI CRI Annual Meeting

Retrieved on: 
Tuesday, August 24, 2021
University, SWOG, Cancer, University of Kansas Medical Center, CRI, EMR, EDC, Children's Mercy Hospital, EHR, Electronic data capture, National Cancer Institute, Biotechnology, Multimedia, NCI, Solution, Organization, Eye, Data science, KUMC, Department, AACI, Pharmaceutical industry

FREMONT, Calif., Aug. 24, 2021 /PRNewswire/ -- The 2021 AACI Clinical Research Innovation (CRI) Meeting was held virtually on July 13-15, 2021.

Key Points: 
  • FREMONT, Calif., Aug. 24, 2021 /PRNewswire/ -- The 2021 AACI Clinical Research Innovation (CRI) Meeting was held virtually on July 13-15, 2021.
  • The AACI membership comprises 102 of the leading academic and freestanding cancer centers in North America.The 2021 AACI CRI Meeting had record attendance with over 1,000 attendees.
  • nCoup, through its nCartes Electronic Health Record (EHR) to Electronic Data Capture (EDC) platform, was pleased to contribute to the information exchange that occurred at the meeting.
  • Several years ago, nCoup began work on its next generation EHR to EDC platform called nCartes.

Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

Retrieved on: 
Wednesday, November 4, 2020
Drug discovery, Pharmaceuticals policy, KUMC, Orphan drug, Life sciences, Health sciences, Health

We have continued to meet our milestones and meaningfully advance our pipeline, said Dr. Neal Walker, President & CEO of Aclaris.

Key Points: 
  • We have continued to meet our milestones and meaningfully advance our pipeline, said Dr. Neal Walker, President & CEO of Aclaris.
  • Aclaris initiated this trial and filed for orphan drug designation for the indication in November 2020.
  • Aclaris is providing funding and clinical drug supply to theUniversity of Kansas Medical Center(KUMC), the sponsor of the trial.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights

Retrieved on: 
Friday, August 7, 2020
Health, Autoinflammatory syndromes, Branches of biology, Cryopyrin-associated periodic syndrome, Clinical research, Drug discovery, Pharmaceutical industry, Caps, KUMC, Clinical trial, NALP3

Aclaris resumed enrolling subjects, and the first subject was dosed, in May 2020.

Key Points: 
  • Aclaris resumed enrolling subjects, and the first subject was dosed, in May 2020.
  • ATI-450-CAPS-201: Aclaris expects to initiate a Phase 2a clinical trial of ATI-450 in cryopyrin-associated periodic syndrome (CAPS), an IL1-driven disease, in the second half of 2020.
  • Aclaris is providing funding and clinical drug supply to theUniversity of Kansas Medical Center(KUMC), the sponsor of the trial.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.